ELI 007
Alternative Names: ELI-007Latest Information Update: 21 Nov 2024
Price :
$50 *
At a glance
- Originator Elicio Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gastrointestinal cancer
Most Recent Events
- 13 Nov 2024 Elicio Therapeutics plans clinical trial for Gastrointestinal cancer in H1 2025 (Parenteral)
- 05 Apr 2024 Pharmacodynamics data from preclinical studies in Gastrointestinal cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 03 Nov 2023 Pharmacodynamics data from preclinical studies in Gastrointestinal cancer released by Elicio Therapeutics